We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.18 | -1.27% | 91.90 | 91.45 | 92.00 | 94.03 | 91.33 | 93.99 | 1,753,124 | 16:40:00 |
From May 2019 to May 2024
By Joshua Kirby
Sanofi SA said Monday that it has agreed to acquire Dutch clinical-stage immunotherapy company Kiadis Pharma NV.
The French pharmaceutical company said it had entered into a definitive agreement to buy all of Kiadis's share capital for a price of EUR5.45 a share via a public offer. The price represents an aggregate adjusted equity value of 308 million euros ($358.7 million), and the deal is subject to certain conditions.
Kiadis develops cell-based immunotherapy products for the treatment of life-threatening diseases, Sanofi said.
"We believe the Kiadis 'off-the-shelf' K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi's emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches," John Reed, global head of research and development at Sanofi, said.
Write to Joshua Kirby at joshua.kirby@dowjones.com
(END) Dow Jones Newswires
November 02, 2020 01:48 ET (06:48 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
